Investors focused on the Consumer Staples space have likely heard of MEDIFAST INC (MED), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.
MEDIFAST INC is one of 177 companies in the Consumer Staples group. The Consumer Staples group currently sits at #15 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MED is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for MED's full-year earnings has moved 40.38% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, MED has gained about 84.43% so far this year. At the same time, Consumer Staples stocks have lost an average of 12.09%. This shows that MEDIFAST INC is outperforming its peers so far this year.
Looking more specifically, MED belongs to the Food - Miscellaneous industry, which includes 42 individual stocks and currently sits at #178 in the Zacks Industry Rank. On average, this group has lost an average of 11.42% so far this year, meaning that MED is performing better in terms of year-to-date returns.
Going forward, investors interested in Consumer Staples stocks should continue to pay close attention to MED as it looks to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDIFAST INC (MED) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research